3 Reasons to Buy Express Scripts

Jim Mueller and Austin Smith, The Motley Fool
Updated

In this video, Austin Smith interviews Jim Mueller, author of the Fool's premium report on Express Scripts. Jim thinks the company is a buy for three reasons:

  • $290 billion of drugs are coming off-patent over the next five years, and the company can benefit from selling more profitable generics.

  • The U.S. and European populations are aging.

  • Obamacare will bring many more people onto the rolls.

For more details, check out the video.

Do lower costs = profits for your portfolio?
In 2011, a massive shift began. With the first of the baby boomer generation reaching Medicare age, America's health-care landscape was forever changed. Combine the aging population with the impact of Obamacare, and the need for innovative solutions for skyrocketing health-care costs is as clear as ever. Express Scripts is part of that solution, and in this brand-new premium report on the company, we clearly lay out the opportunity in front of this misunderstood stock. Claim your copy by clicking here now.


The article 3 Reasons to Buy Express Scripts originally appeared on Fool.com.

Austin Smith owns shares of Pfizer. Jim Mueller has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement